Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Blackstone nears deal to take control of debt-laden Hong Kong developer New World
Blackstone nears deal to take control of debt-laden Hong Kong developer New World Blackstone is in advanced talks to become the largest shareholder in New World Development, in a transaction that would mark one of the most significant private equity interventions in...
Thoma Bravo-backed Anaplan moves towards return to public markets
Thoma Bravo-backed Anaplan moves towards return to public markets Anaplan is preparing to file confidentially for an initial public offering, signalling a potential public-market exit for Thoma Bravo nearly four years after the private equity firm took the software...
Bain and Blackstone advance in auction for UK vitamins group Vitabiotics
Bain and Blackstone advance in auction for UK vitamins group Vitabiotics Bain Capital and Blackstone have emerged as leading contenders in the sale process for Vitabiotics, the UK supplements manufacturer behind some of the country’s best-known vitamin brands,...